||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


CORRECTION (UPDATED LINK): VIFOR PHARMA GROUP REPORTS STRONG H1 2018 RESULTS, RAISES FULL-YEAR GUIDANCE

Vifor Pharma Ltd. /
CORRECTION (UPDATED LINK): VIFOR PHARMA GROUP REPORTS STRONG H1 2018 RESULTS,
RAISES FULL-YEAR GUIDANCE
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

* Strong financial performance in H1 2018
* Three medium-term strategic growth drivers fully on track
* Strategic in-licensing deal concluded with Cara Therapeutics Inc.
* Net sales and EBITDA guidance for 2018 raised and positive outlook confirmed

IN H1 2018, VIFOR PHARMA RECORDED A STRONG FINANCIAL PERFORMANCE DRIVEN BY ITS
THREE STRATEGIC GROWTH DRIVERS. AS A RESULT OF THE STRONG H1 2018 FINANCIAL
PERFORMANCE, THE COMPANY IS RAISING ITS NET SALES AND EBITDA GUIDANCE FOR 2018
AND CONFIRMING THE POSITIVE OUTLOOK.

Corrected with updated link: For the full version of the press release in
English, please click here.

+------------------------------------------------------------------------------+
|  |
|FINANCIAL PERFORMANCE: STRONG GROWTH TREND CONTINUES |
| * Significant revenue growth with net sales of CHF 747.4 million, up 23.4% |
| * EBITDA increased to CHF 192.0 million, up 44.5% |
| * Strong balance sheet with equity ratio of 80.0% |
| |
|THREE STRATEGIC GROWTH DRIVERS FULLY ON TRACK |
| * Strong growth reported in each of the three strategic growth drivers - |
| Ferinject®, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and |
| Veltassa® |
| * Implementation of Milestone 2020 strategic plan in-line with all |
| objectives |
| |
|FERINJECT® |
| * Net sales up 29.3% in H1; on track for growth in excess of 20% for the FY |
| 2018 |
| * Increase in overall i.v. iron market share to 45.7% compared to 39.8% the |
| prior year. |
| |
|VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA |
| * Mircera® growth strong at CHF 214.0 million, up 38.1% from H1 2017. |
| * Conditional Marketing Application accepted (phase-II data basis) and in |
| review for avacopan for the treatment of ANCA-associated vasculitis in |
| Europe |
| * Agreement signed with Cara Therapeutics to develop and commercialise |
| CR845/difelikefalin injection for haemodialysis patients with pruritus |
| worldwide outside US, Japan, South Korea |
| |
|VELTASSA®  |
| * Strong momentum, with net sales of CHF 36.8 million for H1 2018 (up 51.8% |
| from CHF 24.3 million in H1 2017) |
| * Launches in Germany, the UK, and Switzerland |
| * First successful ex-US reimbursement approval in Sweden and Denmark |
| * US Food & Drug Administration (US FDA) approves label change enabling |
| Veltassa® to be taken with or without food |
| * Exclusive development and marketing licence signed with Zeria in Japan |
| |
|NET SALES AND EBITDA GUIDANCE RAISED, POSITIVE OUTLOOK CONFIRMED |
| * Net sales expected to grow by more than 15% |
| * EBITDA expected to increase by more than 25% |
| * All other elements of financial guidance as of 15 March 2018 and positive |
| outlook confirmed |
|  |
+------------------------------------------------------------------------------+


Commenting on the first-half results, Etienne Jornod, Executive Chairman of
Vifor Pharma Group, said: "In the first half of 2018, we continued to build on
our achievements in 2017, executing against our strategy to become a global
leader in iron deficiency, nephrology and cardio-renal therapies. Our three
strategic growth drivers all performed strongly. Ferinject(®)/Injectafer(®)
continued to build on its position as the market-leading intravenous iron
therapy worldwide, with growth of more than 29%, and is on track to grow at
least 20% this year. Our joint company VFMCRP further strengthened its position
in the nephrology market, helped by key products including Mircera(®), which was
up more than 38%. Hyperkalaemia therapy Veltassa(®) is performing in accordance
with our expectations, strengthening our strategic position in cardio-renal
therapies and our overall position in the key US market.

"Based on these results, we are increasing our full-year guidance, with net
sales now expected to grow by more than 15% in 2018 at constant exchange rates
and EBITDA expected to increase by more than 25%."

FINANCIAL PERFORMANCE

+--------------------------------------------------+-------+-------+-----------+
|In million CHF |H1 2018|H1 2017|Change in %|
+--------------------------------------------------+-------+-------+-----------+
|Net sales |747.4 |605.9 |23.4% |
+--------------------------------------------------+-------+-------+-----------+
|EBITDA |192.0 |132.9 |44.5% |
+--------------------------------------------------+-------+-------+-----------+
|Net profit after minorities (from continuing |118.0 |-9.6 |-- |
|operations) | | | |
+--------------------------------------------------+-------+-------+-----------+
|Core earnings per share |2.66 |0.61 |336.1% |
+--------------------------------------------------+-------+-------+-----------+
For further details, please see the Vifor Pharma Group 2018 Half-year Report
(PDF) at www.viforpharma.com.


+------------------------------------------------------------------------------+
|Live conference call and webcast |
|Vifor Pharma will host a live conference call (see phone numbers below) and |
|webcast ((https://edge.media-server.com/m6/p/9bx3fhce) on 8 August 2018 at |
|2:00 p.m. (CET). The pin code for the live conference call is 8528258. |
| |
|Phone numbers for the live Local Free |
|conference call +41 22 567 5750 0800 222 801 |
|Switzerland: +33 1 76 77 2257 0805 101 278 |
|France: +49 69 2222 2018 0800 101 1732 |
|Germany: +44 330 336 9411 0800 279 7204 |
|United Kingdom: +1 323 794 2588 888-394-8218 |
|United States of America: +44 330 336 9411 |
|Other countries: |
| |
|Replay |
|A webcast replay ((https://edge.media-server.com/m6/p/9bx3fhce) will be |
|available from 8 August 2018 at approximately 5:00 p.m. (CET). |
+------------------------------------------------------------------------------+


FURTHER INFORMATION
Media Relations Investor Relations
Heide Hauer Julien Vignot
Head of Corporate Communications Head of Investor Relations
Tel.: +41 58 851 80 87 Tel.: +41 58 851 66 90
E-mail: media@viforpharma.com E-mail: investors@viforpharma.com


Vifor Pharma Group is a global pharmaceuticals company. It aims to become the
global leader in iron deficiency, nephrology and cardio-renal therapies. The
company is the partner of choice for pharmaceuticals and innovative patient-
focused solutions. Vifor Pharma Group strives to help patients around the world
with severe and chronic diseases lead better, healthier lives. The company
develops, manufactures and markets pharmaceutical products for precision patient
care. Vifor Pharma Group holds a leading position in all its core business
activities and consists of the following companies: Vifor Pharma; Vifor
Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical
Care; Relypsa; and OM Pharma. Vifor Pharma Group is headquartered in
Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN,
ISIN: CH0364749348). For more information, please visit www.viforpharma.com.

PRESS RELEASE:
http://hugin.info/148637/R/2209821/860077.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Vifor Pharma Ltd. via GlobeNewswire



 
 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.086 Sekunden